References
- 1. Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol. 1994; 165(1): 243–256.
- 2. Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015; 11(6): 1164-78.
- 3. Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci. 1998; 11: 234–45.
- 4. Carrasco MA, Castro P, Sepulveda FJ, Tapia JC, Gatica K, Davis MI, Aguayo LG. Regulation of glycinergic and GABAergic synaptogenesis by brain-derived neurotrophic factor in developing spinal neurons. Neuroscience. 2007; 145(2): 484–494.
- 5. Donovan MJ, Miranda RC, Kraemer R, et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol. 1995; 147: 309–24.
- 6. Levada OA, Cherednichenko NV. [Brain-derived neurotrophic factor (BDNF): neurobiology and marker value in neuropsychiatry]. Lik Sprava. 2015; (3-4): 15-25.
- 7. Hashimoto R, Ohi K, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Watanabe Y, Fukunaga M, Takeda M. Imaging Genetics and Psychiatric Disorders. Curr Mol Med. 2015; 15(2): 168–175.
- 8. Kim A, Fagan AM, Goate AM, Benzinger TLS, Morris JC, Head D. Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory. Cogn Affect Behav Neurosci. 2015; 15: 625–643.
- 9. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991; 350 (6315): 230–232.
- 10. Segal RA, Takahashi H, McKay RD. Changes in neurotrophin responsiveness during the development of cerebellar granule neurons. Neuron. 1992; 9(6): 1041–1052.
- 11. Oppenheim RW, Yin QW, Prevette D, Yan Q. Brain-derived neurotrophic factor rescues developing avian motoneurons from cell death. Nature. 1992; 360(6406): 755–757.
- 12. Johnson JE, Barde YA, Schwab M, Thoenen H. Brain-derived neurotrophic factor supports the survival of cultured rat retinal ganglion cells. J Neurosci. 1986; 6(10): 3031–3038.
- 13. Elkabes S, DiCicco-Bloom E.M, Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J. Neurosci. 1996; 16, 2508e2521.
- 14. Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, Donnan GA, Howells DW. Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor. The Journal of Neuroscience, March 1, 1999; 19(5): 1708–1716.
- 15. Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. Neuroimmunol 2005; 160(1-2):204-9.
- 16. Rosenthal A, Goeddel DV, Nguyen T, Martin E, Burton LE, Shih A, Laramee GR, Wurm F, Mason A, Nikolics K, Winslon JW: Primary structure and biological activity of human brain-derived neurotrophic factor. Endocrinology 1991; 129: 1289-1294.
- 17. Yamamoto M, Sobue G, Yamamoto K, Terao S, Mitsuma T: Expression of mRNAs for neurotrophic factors (NGF, BDNF, NT-3, and GDNF) and their receptors (p75NGFR, trkA, trkB, and trkC) in the adult human peripheral nervous system and nonneural tissues. Neurochem Res 1996; 21: 929-938.
- 18. Katoh-Semba R, Takeuchi IK, Semba R, Kato K: Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. J Neurochem 1997; 69: 34-42.
- 19. Scarisbrick IA, Jones EG, Isackson PJ: Coexpression of mRNAs for NGF, BDNF, and NT-3 in the cardiovascular system of the pre- and postnatal rat. J Neurosci 1993; 13: 875-893.
- 20. Maroder M, Bellavia D, Meco D, Napolitano M, Stigliano A, Alesse E, Vacca A, Giannini G, Frati L, Gulino A, Screpanti I: Expression of trKB neurotrophin receptor during T cell development: role of brain derived neurotrophic factor in immature thymocyte survival. J Immunol 1996; 157: 2864-2872.
- 21. Matsuda S, Fujita T, Kajiya M, Takeda K, Shiba H, Kawaguchi H, Kurihara H. Brain-derived neurotrophic factor induces migration of endothelial cells through a TrkB-ERK-integrin αVβ3-FAK cascade. J Cell Physiol. 2012; 227(5): 2123-9.
- 22. Dormady SP, Bashayan O, Dougherty R, Zhang XM, Basch RS. Immortalized multipotentialmesenchymal cells and the hematopoietic microenvironment. J Hematother Stem Cell Res. 2001; 10(1): 125-40.
- 23. Dwivedi Y. Involvement of Brain-Derived Neurotrophic Factor in Late-Life Depression. Am J Geriatr Psychiatry. 2013; 21(5): 433–449.
- 24. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res. 2007; 85(3): 525-35.
- 25. Akyol ES, Albayrak Y, Beyazyuz M, Aksoy N, Kuloglu M, Hashimoto K. Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome. Neuropsychiatr Dis Treat. 2015; 11: 865-72.
- 26. Diniz B.S, Teixeira A.L, Machado-Vieira R, Talib L.L, Radanovic M, Gattaz W.F, Forlenza O.V. Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression. Journals of Gerontology, Series B: Psychological Sciences and Social Sciences, 2014; 69(6): 845–851.
- 27. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, Mahadik SP. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol. 2010; 13(4): 535-9.
- 28. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998; 37(12): 1553-61.
- 29. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci. 2014; 8: 430.
- 30. Eyre H, Baune BT. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology. 2012; 37(9): 1397-1416.
- 31. Zha XM, Bishop JF, Hansen MR, Victoria L, Abbas PJ, Mouradian MM, Green SH. BDNF synthesis in spiral ganglion neurons is constitutive and CREB-dependent. Hear Res. 2001; 156 (1-2): 53-68.
- 32. Murphy PG, Borthwick LA, Altares M, Gauldie J, Kaplan D, Richardson PM. Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. Eur J Neurosci 2000; 12(6): 1891-9.
- 33. Lapchak PA, Araujo DM, Hefti F. Systemic interleukin-1 betadecreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience. 1993; 53(2): 297–301.
- 34. Tong L, Prieto GA, Kramár EA, Smith ED, Cribbs DH, Lynch G, Cotman CW. Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase. J Neurosci 2012; 32: 17714-24.
- 35. Böni-Schnetzler M, Donath MY. Increased IL-1β activation, the culprit not only for defective insulin secretion but also for insulin resistance? Cell Res. 2011; 21(7): 995-7.
- 36. Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging 2008; 29(9): 1380-93.
- 37. Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H, Suzumura A. Production and functions of IL-17 in microglia. J Neuroimmunol. 2008; 194(1-2): 54-61.
- 38. Lin G, Zhang H, Sun F, Lu Z, Reed-Maldonado A, Lee YC, Wang G, Banie L, Lue TF. Brain-derived neurotrophic factor promotes nerve regeneration by activating the JAK/STAT pathway in Schwann cells. Transl Androl Urol. 2016; 5(2): 167-75.
- 39. Liongue C, O’Sullivan LA, Trengove MC, Ward AC. Evolution of JAK-STAT pathway components: mechanisms and role in immune system development. PLoS One. 2012; 7(3): e32777.
- 40. Dugan AM, Parrott JM, Redus L, Hensler JG, O’Connor JC. Low-Level Stress Induces Production of Neuroprotective Factors in Wild-Type but Not BDNF+/− Mice: Interleukin-10 and Kynurenic Acid. Int J Neuropsychopharmacol 2015; 19(3): pyv089.
- 41. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron. 1991; 7(5): 695-702.
- 42. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009; 5(6): 311-22.
- 43. Hori H, Yoshimura R, Katsuki A, Atake K, Igata R, Konishi Y, Nakamura J. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. World J Biol Psychiatry. 2016; 13: 1-30.
- 44. Castrén E, Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. Neurobiol Dis. 2016; pii: S0969-9961(16)30169-3.
- 45. Mansur RB, Santos CM, Rizzo LB, Asevedo E, Cunha GR, Noto MN, Pedrini M, Zeni-Graiff M, Cordeiro Q, Vinberg M, Kapczinski F, McIntyre RS, Brietzke E. Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. Bipolar Disord. 2016; 18(4): 373-8.
- 46. Zsuga J, Tajti G, Papp C, Juhasz B, Gesztelyi R. FNDC5/irisin, a molecular target for boosting reward-related learning and motivation. Med Hypotheses. 2016; 90: 23-8.
- 47. Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience. 2003; 119(3): 767-75.
- 48. Fumagalli F, Bedogni F, et al. Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. Eur J Neurosci. 2004; 20(5): 1348–1354.
- 49. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, Lee IH, Chen PS, Yeh TL, Huang SY, Yang YK, Lu RB, Hong JS. J. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. Neuroimmune Pharmacol. 2012; 7(3): 656-64.
- 50. Strube W, Nitsche MA, Wobrock T, Bunse T, Rein B, Herrmann M, Schmitt A, Nieratschker V, Witt SH, Rietschel M, Falkai P, Hasan A. BDNF-Val66Met-Polymorphism Impact on Cortical Plasticity in Schizophrenia Patients: A Proof-of-Concept Study. International Journal of Neuropsychopharmacology. 2015: 18(4): pyu040.
- 51. Leonard BE, Schwarz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol. 2012; 26(5 Suppl): 33-41.
- 52. Monji A, Kato T.A, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, Yamauchi Y, Yamada S, Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013; 42: 115–121.
- 53. Kato TA, Monji A, Mizoguchi Y, Hashioka S, Horikawa H, Seki Y, Kasai M, Utsumi H, Kanba S. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a ‘fire extinguisher’ in the brain of schizophrenia? Mini Rev Med Chem. 2011; 11(7): 565-74.
- 54. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res. 2012; 46 (11): 1421-6.
- 55. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, Lukic ML. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res. 2013; 147 (1): 103-9.
- 56. Stefanović V, Mihajlović G, Nenadović M, Dejanović SD, Borovcanin M, Trajković G. Vojnosanit Pregl. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia. 2015; 72(12):1085-92.
- 57. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, Lukic ML. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia. Psychoneuroendocrinology. 2015; 56: 143-7.
- 58. Borovcanin M, Jovanovic I, Djukic Dejanovic S, Radosavljevic G, Arsenijevic N, Lukic ML. Possible role of TGF-β pathways in schizophrenia. Ser J Exp Clin Res 2016; 17 (1): 3-8.
- 59. Noto CS, Gadelha A, Belangero SI, Smith MAC, W. de Aguiar B, Panizzuti B, Mari JJ, Gama CS, Bressan RA, Brietzke E. Association of biomarkers and depressive symptoms in schizophrenia. Neuroscience Letters. 2011; 505(3): 282–5.
- 60. Zhang XY, Tan YL, Chen DC, Tan SP, Yang FD, Wu HE, Zunta-Soares GB, Huang XF, Kosten TR, Soares JC. Interaction of BDNF with cytokines in chronic schizophrenia. Brain Behav Immun. 2016; 51: 169-75.
- 61. Mahendran R, Mahendran R, Chan YH. Interleukin-2 levels in chronic schizophrenia patients. Ann Acad Med Singapore. 2004; 33(3): 320-3.
- 62. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, Perrin M, Gorman JM, Susser ES. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004; 161(5): 889-95.
- 63. Pirildar S, Gonul AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(4): 709-13.
- 64. Zhang XY, Liang J, Chen da C, Xiang, Hong Xiu M, Yang FD, Kosten A. T, Kosten R. T. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl). 2012; 222: 277-84.
- 65. Green M.J, Matheson S.L, Shepherd A, Weickert C.S, Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol. Psychiatry. 2011; 16 (9): 960–972.
- 66. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res. 2003; 71(1): 127-31.
- 67. Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, Chen da C, Kosten TR, Zhang XY. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(8): 1508-12.
- 68. Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, Nakano Y, Shinkai K, Mitoma M, Ohta M, Shinkai T, Nakamura J. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(5): 1072-7.
- 69. Holt RI, Bushe C and Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol. 2005; 19 (Suppl.6): 56–65.
- 70. Jin H, Meyer JM, Mudaliar S and Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008; 100: 70–85.
- 71. Zhang Y, Chen M, Wu Z, Chen J, Yu S, Fang Y, Zhang C. Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. PLoS One. 2013; 8(8): e72652.
- 72. Gajewska E, Sobieska M, Łojko D, Wieczorowska-Tobis K, Suwalska A. Obesity itself does not influence BDNF serum levels in adults. Eur Rev Med Pharmacol Sci. 2014; 18(21): 3246-50.
- 73. Chaldakov GN, Fiore M, Hristova MG, Aloe L. Metabotrophic potential of neurotrophins: implication in obesity and related diseases? Med Sci Monit. 2003; 9(10): HY19-21.
- 74. Pedersen MS, Benros ME, Agerbo E, Borglum AD, Mortensen PB. Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. Schizophr Res. 2012; 138(1): 58-62.
- 75. Prakash YS, Martin RJ. Brain-derived neurotrophic factor in the airways. Pharmacol Ther. 2014; 143(1): 74-86.
- 76. Watanabe T, Fajt ML, Trudeau JB, Voraphani N, Hu H, Zhou X, Holguin F, Wenzel SE. Brain-Derived Neurotrophic Factor Expression in Asthma. Association with Severity and Type 2 Inflammatory Processes. Am J Respir Cell Mol Biol. 2015; 53(6): 844-52.
- 77. Pae CU, Yoon CH, Kim TS, Kim JJ, Park SH, Lee CU, Lee SJ, Lee C, Paik IH. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol. 2006; 6(4): 666-71.
- 78. Lu J, Kang J, Zhang C, Zhang X. The role of IL-33/ST2L signals in the immune cells. Immunol Lett. 2015; 164(1): 11-7.
- 79. Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature. 2015; 519 (7542): 242-6.
- 80. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, Huang LC, Johnson D, Scanlon ST, McKenzie AN, Fallon PG, Ogg GS. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013; 210(13): 2939-50.
- 81. Raap U, Goltz C, Deneka N, Bruder M, Renz H, Kapp A and Wedi B. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compaired with that seen in nonatopic subjects. J Allergy Clin Immunol. 2005; 115(6):1268-75.
- 82. Zipris P, Melamed Y, Weizman A, Bleich A. Clozapine-Induced Eosinophilia and Switch to Quetiapine in a Patient with Chronic Schizophrenia with Suicidal Tendencies. Isr J Psychiatry Relat Sci. 2007; 44(1): 54-6.
- 83. Jin P, Andiappan AK, Quek JM, Lee B, Au B, Sio YY, Irwanto A, Schurmann C, Grabe HJ, Suri BK, Matta SA, Westra HJ, Franke L, Esko T, Sun L, Zhang X, Liu H, Zhang F, Larbi A, Xu X, Poidinger M, Liu J, Chew FT, Rotzschke O, Shi L, Wang de Y. A functional brain-derived neurotrophic factor (BDNF) gene variant increases the risk of moderate-to-severe allergic rhinitis. J Allergy Clin Immunol. 2015; 135(6): 1486-93.